About Saga Diagnostics
Saga Diagnostics is a Healthcare company based in Lund (Sweden) founded in 2016, and was acquired by Foundation Medicine in April 2026. Tests for circulating tumor DNA detection and analysis are offered. Saga Diagnostics has raised $17.87 million across 8 funding rounds from investors including Foundation Medicine, European Union and Segulah Medical Acceleration. Saga Diagnostics offers products and services including MRD Testing Platform and Liquid Biopsy Test. Its focus areas include Life Sciences, Clinical Genomics, Sequencing Based and Liquid Biopsy. Its legal entity is SAGA Diagnostics AB.
Company details
Saga Diagnostics was founded in 2016 in Lund, Sweden, and operates in the biotechnology sector focused on oncology diagnostics. Next-generation sequencing and proprietary algorithms are utilized to identify cell-free tumor DNA in blood samples. Products such as SAGAsafe, SAGAsign, and SAGAseq are developed to detect mutations and assess therapeutic responses. Services for analyzing gene and chromosomal mutations are also provided to support clinical research and patient monitoring.
- Headquarters Lund, Sweden
- Stage Acquired
- SectorsHealthcare
- Website sagadiagnostics.com
- Social LinkedIn X
- Acquired by Foundation Medicine (Apr 2026)
- Legal Name Saga Diagnostics Ab
- Annual Revenue$2.92 M (USD)434as on Dec 31, 2022
- Net Profit-$2.63 M (USD)as on Dec 31, 2022
- EBITDA-$2.63 M (USD)as on Dec 31, 2022
- Total Equity Funding$17.87M (USD)
in 8 rounds
- InvestorsFoundation Medicine
& 11 more
- Acquired byFoundation Medicine
(Apr 2026)
Products & Services of Saga Diagnostics
Saga Diagnostics offers a comprehensive portfolio of products and services, including MRD Testing Platform and Liquid Biopsy Test.
Detects residual cancer cells via liquid biopsy for personalized oncology care.
Monitors tumor variants in blood to assess treatment response and recurrence.
Funding Insights of Saga Diagnostics
Saga Diagnostics has successfully raised a total of $17.87M across 8 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $17.87M
- Total Rounds 8
- First Round $37,000
(Apr 2016)
- Investors Count 11
All 8 funding rounds of Saga Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2023 | Series A | – | – | – | |
| Jun 2021 | $12.47M | Series A | – | Segulah Medical Acceleration | |
| Feb 2021 | $225,107 | Grant | – | – | |
| Jun 2019 | $4.2M | Series A | – | Hadean Ventures | |
| May 2018 | $58,038 | Grant | – | – | |
| Mar 2018 | $1.2M | Seed | – | LU Innovation, Torna Kapital | |
| Dec 2017 | $59,476 | Grant | – | – | |
| Apr 2016 | $37,000 | Grant | – | – | – |
12 investors in total: 9 institutional and 3 angel.
Investors in Saga Diagnostics
Saga Diagnostics has secured backing from 12 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Foundation Medicine, European Union and Segulah Medical Acceleration.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| hadeanventures.com | ||||
Investment support is provided for life science and high tech. | 2000 | farocapital.se | Lund, Sweden | |
Government agency and accelerator focusing on innovative startups and SMEs | eicfund.eu | Brussels, Belgium | ||
Invests in medical devices, diagnostics, and healthtech for growth stages in Europe. | 2020 | segulahmedical.com | Stockholm, Sweden | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Cancer research funding is provided by Gunnar Nilssons Cancerstiftelse. | cancerstiftelsen.se | Stockholm, Sweden | ||
Support is provided for innovation and commercialization at Lund University. | innovation.lu.se | Lund, Sweden | ||
CF Christer Fahraeus | Swedish entrepreneur, inventor, and angel investor in Indian startups. | unknown_7645f77ecbad405a8 | ||
GN Gunnar Nilsson | unknown_b724900fb52b42758 |
Investor details for Saga Diagnostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Saga Diagnostics
19 people are tracked at Saga Diagnostics (17 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Colby Jenkins | Director, Medical Science Liaison | Leadership |
Brenton Foretich | Vp, Operations | Leadership |
Christopher Vandepas | Senior Director Program Management | Leadership |
Sofia Birkeälv | Associate Director Clinical Research | Leadership |
Henrik Simonsen | Director, Finance | Leadership |
Mark Landers | Senior Vice President Biopharma Partnerships | Leadership |
Anthony George | Co-founder & Director, Digital PCR | Leadership |
Peter Collins | CEO | Leadership |
Annina E. Hube | Director of Project Management | Leadership |
Lao Saal | Founder & Chief Operating Officer | Leadership |
Rocco Crescenzo | Chief Medical Officer | Leadership |
Jennifer W. | Associate Director Clinical Operations | Leadership |
Karen Howarth | VP, Clinical Development | Leadership |
Amanda Green | Director, Project Management | Leadership |
Brian Dow | Chief Financial Officer | Leadership |
Daniel Sumarriva | Executive Medical Director | Leadership |
Jason Carey | Senior Director [msls], Medical Affairs | Leadership |
Lucia Oton Gonzalez | Senior Molecular Diagnostics Scientist, Dpcr | Team |
Nuria Seguí Gracia | Senior Scientist & Operations Manager | Team |
Complete people profiles for Saga Diagnostics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Saga Diagnostics
4 dated milestones of Saga Diagnostics across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Saga Diagnostics is founded.
- Funding First funding round of $37K.
- Funding Latest funding round, Series A,.
- Exit Acquired by Foundation Medicine.
Web traffic of Saga Diagnostics
The website of Saga Diagnostics (sagadiagnostics.com) receives about 2.4K visits a month.
- Monthly visits2.4K
▲ 22.5% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Saga Diagnostics
Complete news archive for Saga Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Saga Diagnostics
Saga Diagnostics was founded in 2016.
Saga Diagnostics is headquartered in Lund, Sweden.
Saga Diagnostics is a funded company, having raised a total of $17.87M across 8 funding rounds to date. The company's 1st funding round was a Grant of $37K, raised on Apr 2016.
Annual revenue of Saga Diagnostics is $2.92M as on Dec 31, 2022.
Saga Diagnostics was founded in 2016 in Lund, Sweden, and operates in the biotechnology sector focused on oncology diagnostics. Next-generation sequencing and proprietary algorithms are utilized to identify cell-free tumor DNA in blood samples. Products such as SAGAsafe, SAGAsign, and SAGAseq are developed to detect mutations and assess therapeutic responses. Services for analyzing gene and chromosomal mutations are also provided to support clinical research and patient monitoring.
Saga Diagnostics offers MRD Testing Platform and Liquid Biopsy Test.
Saga Diagnostics has 12 investors. Key investors include Foundation Medicine, European Union, Segulah Medical Acceleration, Hadean Ventures, and Gunnar Nilssons Cancerstiftelse.
Saga Diagnostics operates through Saga Diagnostics Ab.
Yes. Saga Diagnostics was acquired by Foundation Medicine in April 2026.